Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Improved fibrinogen antagonists from DuPont Merck

Jan. 27, 1997

Merck & Co. investigates thrombin inhibitors

Jan. 24, 1997

Thrombin inhibitors submitted to SAR studies at DuPont Merck

Jan. 24, 1997

Toyama discloses antiplatelet agents

Jan. 23, 1997

Integrilin scheduled for review

Jan. 16, 1997

New compounds for heparin reversal disclosed by University of Michigan

Jan. 14, 1997

Schering-Plough selects Corvas thrombin inhibitor for development

Jan. 13, 1997

NO donors claimed by Searle for cardiovascular applications

Jan. 13, 1997

Fibrinogen receptor antagonists under development at E. Merck

Jan. 10, 1997

Thrombin-binding anticoagulant disclosed by Japanese scientists

Jan. 10, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.